Real-world outcomes poster for AYVAKIT in first-line GIST at ASCO 2026. AYVAKIT is currently approved only in PDGFRA D842V-mutant GIST. Watch: response and tolerability data outside the labeled subset.
What’s at stake
AYVAKIT (avapritinib) is a highly selective oral kinase inhibitor developed by Blueprint Medicines that targets activating mutations in KIT and PDGFRα — the dominant oncogenic drivers in gastrointestinal stromal tumors (GIST) and systemic mastocytosis. The drug fits precisely into the ATP-binding pocket of these mutant kinases to block the aberrant signaling driving tumor growth and mast cell accumulation. AYVAKIT is approved for PDGFRA Exon 18 D842V-mutant GIST — a subset previously insensitive to imatinib — and for advanced and indolent systemic mastocytosis; Blueprint is studying avapritinib versus sunitinib in second-line GIST in an ongoing Phase 3 trial.
No primer in glossary yet.
The largest oncology meeting in the world (~40,000 attendees). Early-June; the dominant venue for cancer trial readouts.
- ASCOconferenceAmerican Society of Clinical Oncology Annual Meeting
The largest oncology meeting in the world (~40,000 attendees). Early-June; the dominant venue for cancer trial readouts.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| REC-994 | RXRX | small molecule | oxidative stress modulator (CCM) | READOUT · Nov 26 |
Disclosure trail
- Mar 25, 2026·1mo agopinned · highest confidenceHIGH confPRWINDOWtop claimMAY–MAY2026
“Real-world outcomes data for AYVAKIT in first-line GIST will be presented as a poster at ASCO 2026 (May 29 – June 2, Chicago).”
conf 91%via llm